Approximately 25.8
million Americans have diabetes, according to the National Diabetes Education
Program, making the disease the seventh leading cause of death in the United
States. To put it in monetary perspective, diabetes runs up an annual tab of
$174 billion in total healthcare and related treatment costs.
Boston Therapeutics
is focused on the development and commercialization of novel compounds based on
complex carbohydrate chemistry to address unmet medical needs, including
diabetes. The company’s current product pipeline is comprised of therapies
developed to treat patient populations with Type 2 diabetes, which accounts for
90-95 percent of all diagnosed cases of diabetes in adults.
PAZ320 is Boston
Therapeutics’ chewable drug candidate designed to prevent diabetes and its
complications. The company believes PAZ320 is a safe and effective drug
compound for people with pre-diabetes and diabetes in their daily management of
blood glucose levels, fulfilling an unmet medical need of increasing proportion.
In its phase 2 clinical trial, 45 percent of the patients saw a 40 percent
reduction in the elevation of post meal blood sugar compared to baseline.
IPOXYN, a universal
oxygen carrier, is Boston Therapeutics’ injectable drug candidate for the prevention
of necrosis (premature cell death following ischemia) and ischemic conditions,
which are caused by the shortage of oxygen supply to the tissue due to
restriction in blood supply. Necrosis is the outcome of severe and acute
injury, involved in many pathological conditions, including diabetes. For now,
the only treatment for necrosis is providing oxygen by a high pressure
facility, creating a crucial need to develop drugs for prevention and treatment
of this pathology.
Supported by a
highly dedicated management and advisory team with extensive expertise in
complex carbohydrate chemistry, regulatory affairs, and clinical development,
Boston Therapeutics is well-positioned to advance position as a high-potential
developer of complex carbohydrate-based new chemical entities for the treatment
of diabetes.
For more
information, visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment